🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
14/01/2019 1,0700 USD
12/10/2018 0,9600 USD
12/07/2018 0,9600 USD
12/04/2018 0,9600 USD
11/01/2018 0,7100 USD
12/10/2017 0,6400 USD
12/07/2017 0,6400 USD
11/04/2017 0,6400 USD
11/01/2017 0,6400 USD
12/10/2016 0,5700 USD
13/07/2016 0,5700 USD
13/04/2016 0,5700 USD
13/01/2016 0,5700 USD
13/10/2015 0,5100 USD
13/07/2015 0,5100 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/01/2014 50,66 50,74 49,64 49,83 -2,10% 2,17% 7.055.200
10/01/2014 51,27 51,49 50,76 50,90 -0,62% 1,42% 5.517.700
09/01/2014 50,59 51,65 49,87 51,22 +1,71% 3,52% 6.960.300
08/01/2014 50,63 51,11 50,24 50,36 -0,26% 1,72% 6.811.100
07/01/2014 50,84 51,21 50,30 50,49 +0,20% 1,79% 9.719.900
06/01/2014 52,70 52,70 50,03 50,39 -3,65% 5,07% 11.871.100
03/01/2014 52,25 52,67 51,97 52,30 +0,62% 1,34% 4.794.300
02/01/2014 52,12 52,33 51,52 51,98 -1,57% 1,55% 4.569.100
31/12/2013 52,99 53,06 52,36 52,81 -0,38% 1,32% 3.019.700
30/12/2013 52,73 53,03 52,60 53,01 +0,88% 0,82% 2.898.800
27/12/2013 52,92 53,05 52,38 52,55 -0,83% 1,27% 2.354.100
26/12/2013 52,59 53,06 52,34 52,99 +1,20% 1,37% 2.401.500
24/12/2013 52,78 52,79 52,28 52,36 -0,42% 0,97% 1.747.000
23/12/2013 52,73 52,94 52,24 52,58 -0,02% 1,33% 4.957.700
20/12/2013 52,77 53,01 52,29 52,59 -0,08% 1,36% 12.471.800
19/12/2013 53,21 53,21 52,02 52,63 -3,11% 2,24% 8.383.400
18/12/2013 52,78 54,43 52,22 54,32 +1,29% 4,19% 9.635.600
17/12/2013 53,43 53,92 53,00 53,63 +0,49% 1,72% 7.987.300
16/12/2013 53,42 54,78 52,98 53,37 +1,91% 3,37% 9.846.300
13/12/2013 52,30 52,60 51,84 52,37 -0,04% 1,45% 6.465.300
12/12/2013 52,56 52,62 51,80 52,39 -0,53% 1,56% 7.766.400
11/12/2013 52,67 53,25 52,02 52,67 +1,02% 2,34% 10.775.500
10/12/2013 51,25 54,13 50,72 52,14 +1,82% 6,65% 14.906.900
09/12/2013 51,45 51,81 50,77 51,21 -0,27% 2,02% 5.470.800
06/12/2013 50,17 51,50 50,05 51,35 +3,20% 2,89% 7.285.800
05/12/2013 49,42 50,07 49,05 49,76 +0,18% 2,06% 5.449.100
04/12/2013 49,75 50,29 49,30 49,67 -0,60% 1,99% 5.309.200
03/12/2013 49,13 50,26 48,97 49,97 +3,27% 2,63% 9.480.100
02/12/2013 48,49 48,68 48,02 48,39 -0,12% 1,36% 4.321.900
29/11/2013 48,43 48,93 48,07 48,45 +0,41% 1,78% 4.044.300